Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DEBUNKING the DOUBLE DOWN ON 12 YEAR OLD NEWS !
Look a little deeper. BTW Cytolin was a non humanized drug that predates Leronlimab. That Means that this was before Cytodyn purchased Pro-140.
I will put in a larger slice than you did.
"Sunday, February 21, 2021
CytoDyn, Inc. Prepares for New Clinical of Its First-In-Class Drug for Treating HIV/AIDS
CytoDyn, Inc. is preparing for its next clinical trial of Cytolin, the breakthrough drug for HIV/AIDS that uses the body's own immune system to fight the virus. The preparations come at a time when CytoDyn, Inc. is making big changes that include relocating to a larger facility to accommodate expanded business activities."
Date and first paragraph.
"SANTA FE, NM (PRWEB) OCTOBER 22, 2008
Although HIV and AIDS are substantially more treatable now than during the height of the AIDS epidemic in the 1980s, numerous challenges still face AIDS and HIV patients and AIDS researchers. One major concern is that drug-resistant strains of HIV are emerging globally, but there is hope that Cytolin, a first-in-class AIDS and HIV treatment from CytoDyn, Inc., can help address this problem."
From that Article. a quote from the CEO of Cytodyn ? Same guy listed as CEO back in 2004.
" Allen D. Allen, Chief Executive Officer of CytoDyn, Inc., says the company philosophy is to maintain complete transparency in its operations. Visitors to CytoDyn.com can view the Company's financial records, share price, and a summary that explains the science behind Cytolin with key references to the literature. "
Article on Cytodyn from 2008 ? Embedded in an introduction from this week ?
Someone spent some money to create a false impression.
They must really be worried.
I wonder how much it costs to author and article on that service, of course it would be fraud to change it, so they had to leave the original date on it.
Yes, that is the settlement.
What I am speaking to is the intent at the time the lawsuit was initiated by the investor group.
I am not confused.
The circumstances for Cytodyn have changed. They are very different than they were a year ago.
Financially crippling a company if not settled and the lawsuit was successful means that everybody loses .
Except big pharma.
I worked at a very large US company for a very long time, and while they were very successful, the C- Suite was very good about enriching themselves at the same time they were "wasting" billions with bad decisions. What C- Suite doesn't pay themselves ? millions of shares at less than a dollar makes a good incentive to succeed.
What I wonder at, is the lawsuit brought by insiders at what was a very critical time for Cytodyn. It seems almost like the dollar amount of the lawsuit was meant to cripple Cytodyn at a time when they would have needed an influx of cash instead.
Why would insiders want the company to fail right at the possible take off ?
If it was not for Covid19 and the potential here they might have been successful.
Jmo
Wow, is this a suggestion that he was a criminal mastermind back in 1986 ?
How old was NP back in 1986 ?
How does this have relevance 35 years later ?
Very good explanation.
What is important here is that the potential for earning revenue immediately, if Phase 3 results in an EUA in the US, is exponential.
An EUA in the US would most likely result in EUA or similar approvals in the UK, Canada, European Union, the Philippines and a host of other Countries.
Most Medicines take years for Uptake and earnings to grow. A positive result here is an immediate sale of all existing product and a ramp up of production and sales not to individual Hospitals or Hospital Systems but to Countries.
The potential both short term and long term is astounding !
Good luck with this.
Too bad the the new company chose SGSI to merge with.
A stock symbol that has massive dilution and reverse stock splits. In a relatively rapid succession.
Were the OWNERS re-assigned ??
I watched as they went from Carbon Capture into Formic Salts/ Formic Acid as a precursor into Hydrogen Fuel Cells. The Hydrogen Fuel Cell Demo was a bike that NIKOLA copied when they did the downhill Roll.
Then the 5 G concept except they weren't designing or making anything for 5 G they had a fee divisions that had maintenance or construction contracts adding antennas and RRHs on towers or doing maintenance mainly for Sprint.
Now it's something to do with AI.
This company is like a super sponge that the owners use to soak up money and then they squeeze that money into their personal accounts and shareholders are left with a dry sponge that gets cut into tiny pieces.
I'm surprised they didn't get into anything Covid related.
I can just picture the owners and executives at a retreat in Florida in the middle of a pandemic at happy hour brainstorming the next scam, oops I mean business idea.
Carbon Capture ...ugh nope done that and failed, Hydrogen Fuel Cells burp, nope same failure. Battery Tech...uhhh nope done that and failed. 5 G nope done that failed. Then all if a sudden one guy pipes up about a movie he saw in the hotel room called terminator about an AI that grows self aware and attacks it's human creators....THATS IT ! They all cry in unison.
The new business Idea, born at happy hour in Florida.
Sounds like a Weiner to me. Buy up stock, don't worry they still have to dilute the heck out of it, before they reverse split.
I did not say that CD12 would benefit from CD10.
What I said was that the CD10 results showed that the effect of Leronlimab was more pronounced the more serious the symptoms became.
In essence, easier to measure the difference. Since the patients in the CD12 trial were worse off, the difference would be more measurable.
Its my opinion that the FDA is sitting on it, in fact nobody might be sitting on the data. It may still be getting processed before lock. It is possible that Cytodyn does not have the data yet.
I can speculate on the positive much like what you are doing in the negative, however the truth will eventually come out. The time frame is relatively short.
Once the numbers come out, either Longs win or shorts win.
The anecdotal evidence is what tells you that a therapeutic works and this one has been used to positive effect in many worst case situations.
These cases are where the rubber hits the road and show that when the disease progression is far enough along, the difference in the live or die situations become more pronounced.
This is where there is no ambiguity to muddy results.
for CD10 the argument was.." These people would have gotten better on their own". Except when they don't. Over 400,000 people would have a difference of opinion, if they were alive to voice it.
Those are technicalities.
This was a Phase2 trial not a Phase 3 trial. Not designed for FDA EUA or Acceptance. It was a chance to show the performance and learn about the performance of Leronlimab vs Covid19.
I'm not speaking to the technical aspect of this. They did learn something in CD10.
1) It works, it has a definite positive effect on Covid19 patients. I'm talking performance of the drug, proof that its mechanism works and that it really works the worse off the patient is.
CD10 showed, that CD12 which is for a more severe set of patients has a great chance of being successful.
The ambiguity of CD10 will not be present in CD12. If anything, I believe that CD12 results are so profound, the FDA is looking at data and trying to figure out how they will not be vilified for blocking Leronlimab at the beginning of the Pandemic.
Sitting on data is not something that is a part of NPs personality, however it is something that the FDA is good at. If data was bad they would have forced Cytodyn to announce it immediately, as their initial block of Leronlimab would be proven out.
The silence is telling, but its not telling what Naysayers here want to read into it.
What aspect of CD10 failed ?
The much touted failure of CD10 was not that the treatment did not work .
The wrong endpoint was chosen. The data was too ambiguous in the mild segment. As the patient conditions worsened the benefit of the treatment was more pronounced.
I agree with you on all points about CYDY and Leronlimab.
Especially getting in before the masses.
We just need that first domino to fall and it will start a chain reaction that will run for years.
The fact that is ignored is this.
Why the EINDs allowed to continue for any hospital that request use for a patient ?
Why the extension of the CD12 trial for the participating hospitals ?
The FDA did not come up with these Ideas on their own.
Obviously there was strong interest by some doctors to use Leronlimab after the trial enrollment closed so the EINDs were opened back up as a process to get Leronlimab.
Getting inundated with paperwork most likely spurred the idea to extend the trial to not only simplify access, but to mitigate the flood of paperwork that the FDA had to deal with.
Government as we have witnessed, does not do anything quickly to help people, however they will work quickly to help themeselves to not do more work than possible . That is why the trial was extended, too much demand and too much extra paperwork.
So, if Leronlimab is a failure why would there be any demand ?
If no one was interested in it, due to its failure , why would they even have opened up the EINDs ?
They would have ended the trial and we would just have waited for results.
Best to you Grip.
I agree the time is running out and that it is put up or shut up time with regards to Covid19.
Yup, I mean there really was no choice. acquired in 2017.
Unfortunately some will try to spin this.
OKAY,
Lets say you have CYDY warrants that are about to expire, they are in the MONEY.
Hmmmm, sell or lose all that money, or sell and convert some to stock..tick tock, tick tock what do I do ?
I think the answer is obvious. Pretty Smart lady in my opinion.
They are two complete sets of trials.
CD12 is not dependent on CD10, I did not state this.
The apparent opinion of Cytodyn medical experts is that Leronlimab works against the "Cytokine Storm" induced to some patients who have comtracted Covid. They also seem to have the opinion of treating earlier is better.
When Cytodyn first approached the FDA they were rebuffed, all medical and media was pointing at Anti-Virals as the answer to Covid19 treatment. CCR-5 inhibitors ? who ever heard of that ?
Even Cytodyn medical professionals did not know the extent of where the therapeutic started working. CD10 was as much about pinpointing where in the Covid19 state Leronlimab started working as it was about the proof that it worked.
As I said, CD10 symptoms and effect were too ambiguous to decidedly prove out. Hence them looking at the secondary endpoint which was the NEWS2 result. NEWS2 being a predictive score of when a patient is going to get more serious symptoms and require respiratory support. They scored higher in that respect but it was not a stated goal of the trial.
As you said Phase 3 will be much more cut and dried, how many lived and how many died.
That is what the current bet is. For Most people here.
That is not my bet. My bet is that they will sell their 1.2 million vials of Leronlimab to a country or countries and that 1.2 million patients will be treated for Covid. That's a over 1 billion dollars in revenue.
After that we will see big signs somewhere saying ONE MILLION SURVIVORS CAN"T BE WRONG !
YUP, and the proof that those are related is of course the purchase prices of those 166,000 shares at the nice price of .75 cents, or are the naysayers on the board gonna say she majicked the market into letting her buy that cheap.
Its a Phase 2, phase 2 trials do not get approval. They get to go on to Phase 3.
Cytodyn is a small company with limited resources, they chose not to initiate a Phase 3. They may have expected to get an EUA "wrongly" due to the hype generated in the media about hospitals getting full, and the role they could play in preventing that.
Cytodyn management were naive in that respect.
You say it was a failure due to a failure to get an EUA, the endpoint was not to get an EUA.
The failure of CD10 was the ambiguous nature of the data, not the performance of the therapeutic.
The secondary endpoint which some call data mining is the more significant yield of results anyway. Keeping 67% from advancing to more serious pulmonary complications is still significant. especially when that is how this virus kills.
You are talking to a statistical set of data to verify a pre-determined result/goal. Yes, it was to hard to say with certainty they proved it.
I am talking to the most important aspect of any trial or an pplication of a therapeutic, which simply answers the question ; did any treated patients go to ICU ? In other words DOES THE MEDICATION WORK ?
So you are saying that patients in the CD10 trial got more sick ? Continued on to the ICU ?
CD10 was a Phase II trial. Was not a failure they were told to move on to phase III, they chose not to spend the time and waste the money.
The NEWS2 scores were not data mining they were significant. If anything the management at CYDY were mistaken on thinking that the US FDA and the rest of the Health infrastructure would want to save lives and thought the results were significant enough.
CD12 is a phase 3 and has a large enough patient sample to show significance. That is the bet that is on the line here.
CD12 success will be the first domino. If successful the medicine starts to flow, after that Big numbers will tell.
Keep in mind that CD12 was not about Leronlimab vs Placebo. It was about Leronlimab vs all other SOC + Placebo.
So Leronlimab vs all Big Pharma could throw against it.
Who wins ?
OH NO ! I better sell my stock too !
Isn't that how it's supposed to go ?
LAUGHING !
So how you interpreting the CD10 as a failure?
The effect on NEWS2 in keeping patients out of Critical care was quoted as 67%.
I suppose we could believe you folks and sell our CYDY stock.
However, from seeing and reading the reactions of the doctors who have actually used it and see the emotion on their faces when they speak about it, I as a shareholder don't really have much of a choice.
The choice is between believing someone who cares about saving lives and someone who cares about saving their badly timed investment.
That has been my thought also.
If someone is really intent on shorting CYDY and really does believe the CD12 trial is a failure, then letting it pump up to a higher valuation would be better as it increases the difference between the stock price and .50 which is where their meat is.
What the current behavior indicates is that many shorted below where we are at now. No money left to cover and short higher.
The interesting thing is when the first domino falls , meaning the CD12 success, how does Nader play it ?
If CD12 is successful, and EUA is given by the FDA,all we have to do as shareholders as they distribute Vyrologix and the results start getting noticed around the world.
Not such a bad thing to start with over a billion dollars in immediate , high profit margin earnings and be able to sell all produced Vyrologix.
Yes, today was a very fun day. I think we will have a very fun week.
Not really, that was before the study. The patients were at deaths door.
He did say that they got 4 doses and that the FDA said, 2 doses were sufficient for the Trial.
The tragedy is the ignorance of the FDA.
Look to the future, the past is not a mystery.
Do you drive down the highway and navigate by looking in the rear view mirror ?
Ya gotta inflate that bubble a bit before you pop it.
Somebody has to pay for it....
After next week the shorts can go complain about losing more than $100,000.00 , oh yeah I forgot, they are not really investors. They borrow CYDY stock and sell it, then they buy it to pay back what they borrowed.
That not an investor, that is a vulture.
jmho
There are two things about the posting by the Schall Law Firm which has a great big banner on the YF news Page for CYDY.
First News you see on Cytodyn is the big banner stating in very large letters " ONGOING INVESTIGATION ALERT ". Its big and its bold and most likely meant for new investors looking to see what news there is for Cytodyn. My opinion is that this is a psychological trigger to warn potential investors away from CYDY.
The second point is ironic in that they want to hear from investors that have lost more than $100,000.00 in Cytodyn stock. The irony being that they are a vehicle for that to have happened back in the summer, if an investor bought at the high or close to it then the banner first showed up and an investor sold low to save some of their investment before any lawsuits destroyed it.
I ignore it as propaganda. others might not and that is why that is there.
jmho
CYDY stock is UP !
All of this on a down day for the markets.
S&P 500 - down over 105 pts
NASDAQ - Down over 390 pts
Glad I bought those thousand shares yesterday down in the mid 4s.
TRIPLE DIGITS in the future !
CYDY $5.29 and rising, I-Hub layer 3 Montage showing over 400,000 more buys than sells.
The digits behind the decimal do not count when describing a price in digits such as "single digits" "double digits", "triple digits".
I acquired the majority of my shares down in the $2 to $2.50 range, I am currently actually averaging up in price, but have set a limit under $5/sh to acquire more CYDY stock.
I also have some other stocks that I will sell to build another pile of cash to buy more CYDY if the price remains under $5 for another month.
THE CEO said Cytodyn gonna become a BIG Pharma, not remain a little pharma, cant do that with a drug that is a failure.
I added to my position today, thanks to everyone doing their best to drop the price. Keep up the good work. I like buying for less than $5.
When we reach the TRIPLE DIGITS,NP gonna be referred to as "THE TRIPLE OG "
Have a great day..ps I have an oil royalty check due by the 28th, please help me spend it on an even lower CYDY price.
This is the stock market and anything can happen.
This is also the reason that there are always 2 sides.
Keep in mind the CEO for CYDY never stays silent for long. This is different. You might have the opinion that news could be bad. I might have the opinion that He is silent to kill two birds with one stone.
Bird 1 - Has to wait for report on the Phase III. This takes time, could always make noise like in the past about other indications, but we are not seeing this.
Bird 2 - Taking advantage of wait time to get in a pre-uplisting quiet period so it all hits together.
Right now both your outcome and my outcome are a possibility. In the end, one will be a reality and one of us will win and the other will lose.
Until the specifics are truly known, what I say is speculation and what others say is also speculation hence the jmho.
jmho
What really matters is the price at which shorts would have to cover on CYDY stock.
If results are positive and inventory is sold that would give CYDY over a Billion Dollars revenue with a very high Profit Margin which would then equate to a higher end Price to Earnings.
The revenue would not happen over a period of years. It would not be like a lightswitch being turned on, it would be like a Power Station Coming online. Fast and Massive.
jmho